University of British Columbia, Vancouver, BC, Canada (R.D.T., S.F., J.C., N.M.H., L.S., M.T., S.A.V., B.J.M.D., M.E.S.).
Centre for Advancing Health Outcomes, Vancouver, BC, Canada (R.D.T., S.F., M.E.S.).
Circ Heart Fail. 2024 Apr;17(4):e011445. doi: 10.1161/CIRCHEARTFAILURE.123.011445. Epub 2024 Apr 6.
The development of tools to support shared decision-making should be informed by patients' decisional needs and treatment preferences, which are largely unknown for heart failure (HF) with reduced ejection fraction (HFrEF) pharmacotherapy decisions. We aimed to identify patients' decisional needs when considering HFrEF medication options.
This was a qualitative study using semi-structured interviews. We recruited patients with HFrEF from 2 Canadian ambulatory HF clinics and clinicians from Canadian HF guideline panels, HF clinics, and Canadian HF Society membership. We identified themes through inductive thematic analysis.
Participants included 15 patients and 12 clinicians. Six themes and associated subthemes emerged related to HFrEF pharmacotherapy decision-making: (1) patient decisional needs included lack of awareness of a choice or options, difficult decision timing and stage, information overload, and inadequate motivation, support and resources; (2) patients' decisional conflict varied substantially, driven by unclear trade-offs; (3) treatment attribute preferences-patients focused on both benefits and downsides of treatment, whereas clinicians centered discussion on benefits; (4) quality of life-patients' definition of quality of life depended on pre-HF activity, though most patients demonstrated adaptability in adjusting their daily activities to manage HF; (5) shared decision-making process-clinicians' described a process more akin to informed consent; (6) decision support-multimedia decision aids, virtual appointments, and primary-care comanagement emerged as potential enablers of shared decision-making.
Patients with HFrEF have several decisional needs, which are consistent with those that may respond to decision aids. These findings can inform the development of HFrEF pharmacotherapy decision aids to address these decisional needs and facilitate shared decision-making.
支持共同决策的工具的开发应该以患者的决策需求和治疗偏好为依据,而这些在射血分数降低的心力衰竭(HFrEF)药物治疗决策中很大程度上是未知的。我们旨在确定患者在考虑 HFrEF 药物选择时的决策需求。
这是一项使用半结构化访谈的定性研究。我们从加拿大 2 家门诊心力衰竭诊所招募了 HFrEF 患者和来自加拿大心力衰竭指南小组、心力衰竭诊所和加拿大心力衰竭学会成员的临床医生。我们通过归纳主题分析确定了主题。
参与者包括 15 名患者和 12 名临床医生。与 HFrEF 药物治疗决策相关的六个主题和相关子主题如下:(1)患者的决策需求包括缺乏对选择或方案的认识、决策时机和阶段困难、信息过载以及缺乏动机、支持和资源;(2)患者的决策冲突差异很大,是由不明确的权衡驱动的;(3)治疗属性偏好-患者关注治疗的利弊,而临床医生则集中讨论益处;(4)生活质量-患者对生活质量的定义取决于心力衰竭前的活动,但大多数患者表现出适应能力,以调整日常活动来管理心力衰竭;(5)共同决策过程-临床医生描述的过程更类似于知情同意;(6)决策支持-多媒体决策辅助工具、虚拟预约和初级保健联合管理被认为是共同决策的潜在推动者。
HFrEF 患者有多种决策需求,这些需求与可能对决策辅助工具产生反应的需求一致。这些发现可以为开发 HFrEF 药物治疗决策辅助工具提供信息,以满足这些决策需求并促进共同决策。